Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Steviolbioside is a natural, non-caloric sweetener and a bioactive compound found in small amounts in the leaves of *Stevia rebaudiana*. It is also the main metabolite of the popular sweeteners rebaudioside A and stevioside. Steviolbioside has been used as an intermediate in medication synthesis and as a food additive. Pharmacologically, it exhibits antihyperglycemic, antihypertensive, anti-inflammatory, antituberculosis, and moderate anticancer activities. In vitro studies have shown that steviolbioside inhibits the growth of *Mycobacterium tuberculosis* more effectively than stevioside. It has also demonstrated cytotoxic effects against certain cancer cell lines (such as human breast cancer MDA-MB-231) while being less toxic to normal cells compared to standard chemotherapy agents like 5-fluorouracil. Mechanistically, its actions are thought to involve modulation of glucose transport pathways similar to insulin signaling (PI3K/Akt pathway), but specific molecular targets for steviolbioside itself remain unclear[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on steviolbioside.